Pharmaceutical - Anti-virals


Current filters:


Popular Filters

101 to 125 of 306 results

Janssen-Cilag files European approval of combination medicine for HIV-1


US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C


The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

ViiV Healthcare presents positive Tivicay results from HIV study


Positive data has been reported from the Phase IIIb/IV FLAMINGO study of Tivicay (dolutegravir) versus…

Anti-viralsNorth AmericaPharmaceuticalResearchTivicayViiV Healthcare

AHF sues GSK for failing to provide discounts on HIV/AIDS drugs


The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

Roche in up to $422.5 million deal with Inovio Pharma


Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Boehringer Ingelheim links with Presidio on interferon-free hepatitis C treatment regimens


The US subsidiary of German family-owned drug major Boehringer Ingelheim says it has completed patient…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalPPI-668Presidio PharmaceuticalsResearch

Medivir and Daewoong drop hep C drug candidate


Swedish infectious disease drug developer Medivir (STO:MVIR-B) said on Friday (September 6) that it has…


In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"


As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

FDA approves new ViiV Healthcare HIV drug


The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

AHF claims victory over FDA in HIV prevention drug case


The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

US FDA approves shipment of quadrivalent flu vaccine to health care providers


The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says it has received Food and Drug Administration…

Anti-viralsFluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Roche strikes deal with Medicines Patent Pool on medicines access


Swiss drug major Roche (ROG: SIX) has entered into an agreement with the Medicines Patent Pool, a Geneva,…

Anti-viralsMarkets & MarketingPharmaceuticalPricingRocheValcyte

Vertex slumps as FDA delays hepatitis C trial


US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

New Zealand consults on Victrelis listing and some Pegasys amendments


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children


In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Annual approvals of new drugs for neglected diseases nearly doubled since early 2000s and 2009-12; Tufts


The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent…

Anti-viralsPharmaceuticalRegulationResearchTropical diseases

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Boehringer Ingelheim's all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C


New data from German family-owned drug major Boehringer Ingelheim's interferon-free SOUND-C3, presented…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalResearch

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid


Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the…

Anti-viralsBionor PharmaCelgenePharmaceuticalResearchRevlimidVacc-4xVaccines

BioLineRx collaborates with Chinese firm on hep C drug BL-8030


Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

101 to 125 of 306 results

Company Spotlight



Back to top